Design, Synthesis, Biological Evaluation, and Crystallographic Study of Novel Purine Nucleoside Phosphorylase Inhibitors
Journal of Medicinal Chemistry · 25.05.2023 · 66 (10) · 6652-6681
DOI: 10.1021/acs.jmedchem.2c02097 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 03.05.2023. Verfasst von Jan Skácel und 21 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Organic Chemistry and Biochemistry, The Czech Academy of Sciences, Flemingovo nám. 2, Prague 16610, Czech Republic. Hauptthemen laut MEDLINE: Purine-Nucleoside Phosphorylase, Enzyme Inhibitors. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Technology Agency of the Czech Republic, European Commission, European Regional Development Fund.
Abstract (Originalsprache)
Purine nucleoside phosphorylase (PNP) is a well-known molecular target with potential therapeutic applications in the treatment of T-cell malignancies and/or bacterial/parasitic infections. Here, we report the design, development of synthetic methodology, and biological evaluation of a series of 30 novel PNP inhibitors based on acyclic nucleoside phosphonates bearing a 9-deazahypoxanthine nucleobase. The strongest inhibitors exhibited IC50 values as low as 19 nM (human PNP) and 4 nM (Mycobacterium tuberculosis (Mt) PNP) and highly selective cytotoxicity toward various T-lymphoblastic cell lines with CC50 values as low as 9 nM. No cytotoxic effect was observed on other cancer cell lines (HeLa S3, HL60, HepG2) or primary PBMCs for up to 10 μM. We report the first example of the PNP inhibitor exhibiting over 60-fold selectivity for the pathogenic enzyme (MtPNP) over hPNP. The results are supported by a crystallographic study of eight enzyme-inhibitor complexes and by ADMET profiling in vitro and in vivo.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Organic Chemistry and Biochemistry, The Czech Academy of Sciences, Flemingovo nám. 2, Prague 16610, Czech Republic.
- Faculty of Science, Charles University in Prague, Hlavova 2030/8, Prague 2 12843, Czech Republic.
- University of Chemistry and Technology, Technická 5, Prague 16628, Czech Republic.
- Institute of Molecular Genetics, The Czech Academy of Science, Vídeňská 1083, Prague 14220, Czech Republic.
ORCID-Profile: Filip Kalčic, Zlatko Janeba
Förderung
- Technology Agency of the Czech Republic
- European Commission
- European Regional Development Fund
- Akademie Ved Cesk? Republiky
Zitieren
APA
Skácel, J., Djukic, S., Baszczyňski, O., Kalčic, F., Bílek, T., Chalupský, K., Kozák, J., Dvořáková, A., Tloušt'ová, E., Král'ová, Z., Šmídková, M., Voldřich, J., Rumlová, M., Pachl, P., Brynda, J., Vučková, T., Fábry, M., Snášel, J., Pichová, I., …, & Janeba, Z. (2023). Design, Synthesis, Biological Evaluation, and Crystallographic Study of Novel Purine Nucleoside Phosphorylase Inhibitors. Journal of Medicinal Chemistry, 66(10), 6652-6681. https://doi.org/10.1021/acs.jmedchem.2c02097
Vancouver
Skácel J, Djukic S, Baszczyňski O, Kalčic F, Bílek T, Chalupský K, et al. Design, Synthesis, Biological Evaluation, and Crystallographic Study of Novel Purine Nucleoside Phosphorylase Inhibitors. Journal of Medicinal Chemistry. 2023;66(10):6652-6681. doi:10.1021/acs.jmedchem.2c02097
BibTeX
@article{Skcel2023,
author = {Skácel, Jan and Djukic, Stefan and Baszczyňski, Ondřej and Kalčic, Filip and Bílek, Tadeáš and Chalupský, Karel and Kozák, Jaroslav and Dvořáková, Alexandra and Tloušt'ová, Eva and Král'ová, Zuzana and Šmídková, Markéta and Voldřich, Jan and Rumlová, Michaela and Pachl, Petr and Brynda, Jiří and Vučková, Tereza and Fábry, Milan and Snášel, Jan and Pichová, Iva and Řezáčová, Pavlína and Mertlíková-Kaiserová, Helena and Janeba, Zlatko},
title = {Design, Synthesis, Biological Evaluation, and Crystallographic Study of Novel Purine Nucleoside Phosphorylase Inhibitors},
journal = {Journal of Medicinal Chemistry},
year = {2023},
volume = {66},
number = {10},
pages = {6652--6681},
doi = {10.1021/acs.jmedchem.2c02097}
}
EUVIMED